FuturaGene Overview

2

Agenda Presentation to Goldman Sachs

▪ Introduction

▪ Why Biotech

▪ Our Business

▪ Summary

3

Introduction Brazilian Forestry Biotech Global Champion

Attractive sector; positive industry trends

GM crop deployment has demonstrated high penetration and consistent growth over the last 15 years;

Increasing demand for food and biofuels and decrease of available arable land;

Technological leadership

Fully developed game-changer technology: major increase in commercial eucalyptus yields;

Technology applicable to a broad array of species (trees, sugarcane, inter alia) and geographies;

Unique commercial position

Significant captive market : Suzano forests (~ 10% of Brazilian eucalyptus plantation);

Strong shareholder sponsorship

Financial support by Suzano, a Brazilian leader in the forestry sector;

Access to world’s best commercial eucalyptus genetic base enables broad commercial reach.

4

Introduction Leadership in Forest Biotechnology

To be a world leader in developing and delivering sustainable biotech solutions for global forestry,

biopower and biofuel markets

FuturaGene is positioned to serve the biotechnological needs of all key players in its

strategic market sectors

Key sectors: Plantation forestry, power generation from biomass, production of

2nd generation biofuels and biochemicals

Key platforms: Yield and processability enhancement, Yield protection

Key geographies: Brazil, China and the USA

5

Introduction Agricultural Biotechnology – a closed club

6

Agenda Presentation to Goldman Sachs

▪ Introduction

▪ Why Biotech

▪ Our Business

▪ Summary

7

Why Biotech Meeting the challenges facing modern agriculture

Produce twice as much food in 2050 as is produced today with additional burden of fiber and biofuel demand.

Reduce environmental impact by producing more from each unit of land, water and energy invested in crop production.

Adapt cropping systems to climate changes that threaten productivity and food security.

Adapt cropping systems to rapidly developing pest and disease threats resulting from crop intensification and climate changes.

Develop new technologies that deliver enhanced economic returns for all farmers.

8

Why Biotech Technology and Yield evolution

1st Generation

Single gene traits – herbicide tolerance and insect resistance

1.5 Generation

Stacked traits – herbicide tolerance and insect resistance

in the same plant

Next Generation

Regulation of output and key pathways – yield, nitrogen use

and abiotic stress

Long term Short term

Technology Evolution

Forest Yield Evolution (m³/ha/year)

Yield Enhancement

Yield Maintenance

BIOTECHNOLOGY

29 31 44

21

Clones Monoprogeny planting Soils and nutrition

Conventional improvement

1960 1970 1990 2000 2010

Keys to Success: Regulation of

food, feed and environmental

safety; Public

acceptance

9

Agenda Presentation to Goldman Sachs

▪ Introduction

▪ Why Biotech

▪ Our Business

▪ Summary

10

Our Business History and Evolution

1993

2001

Strategic shift into agricultural

biotechnology

2000

FuturaGene Plc. listed on the AIM, of the

London Stock Exchange

2004

2006

CBD and FuturaGene Plc. merge – traded

in London

Projected First Product

deregulation

2014-15 2010

2001

Suzano acquires 3.6% of CBD Technologies

2009

Suzano increases stake to 9% of

FGN.

2010

Acquisition by Suzano

11

Our Business

FuturaGene Biotechnology China

Shanghai, China

FuturaGene Inc.

Indiana USA

FuturaGene Israel Ltd. Rehovot, Israel

FuturaGene Brazil Ltd. Itapetininga, Brazil

FuturaGene Group Structure

Business Units (Pulp, Paper and Forest)

12

Our Business Global Presence

FuturaGene Brazil

FuturaGene Israel FuturaGene

Biotechnology (Shanghai)

FuturaGene Ltd. UK

FuturaGene

Agridev (Xinjiang)

FuturaGene Inc. USA

32

46 18

# Head count

Updated on May 13

FuturaGene Barcelona

1

13

Our Business Unique synergy across the biotech value chain

FuturaGene business model accommodates partners at all

stages along the biotech value chain

Powerful, proven technology for

yield enhancement;

Ability and efficiency in

eucalyptus transformation;

Access to valuable technology

pipeline (both internally developed

and sourced)

Elite commercial clones: high

performance germplasm for a broad

array of environmental conditions

Experienced in-house regulatory

team

Large scale forest management skills

High volume propagation nurseries in

place

Large captive market – ~10% of

Brazilian eucalyptus commercial forest

estate

Gene / Trait Sourcing

Channel & Customer Services

Prototyping & Regulatory

Commercial Production

Germplasm (classical breeding)

Genetic Transformation

Biomass Off-taker

14

Our Business Unique, proven yield enhancement technology

Biomass Off-taker

Gene / Trait Sourcing

Channel & Customer Services

Prototyping & Regulatory

Commercial Production

Germplasm (classical breeding)

Genetic Transformation

Phase 0 Gene

Discovery

Phase II Early Stage

Phase III Late stage

Phase IV Pre-launch

Phase I Proof of concept

Average Duration

Investment

Genes in testing

24 to 48 months

$ 2 – 5M

Tens of thousands

Average Probability of Success

5%

12 to 24 months

$ 5 –10M

Thousands

25%

12 to 24 months

$ 10 –15M

Tens

50%

12 to 24 months

$ 10 –30M

<5

75%

12 to 36 months

$ 20–40M

1

90%

Source: Monsanto

15

Our Business Summarized Brazilian GM Regulatory Process

Biomass Off-taker

Gene / Trait Sourcing

Channel & Customer Services

Commercial Production

Prototyping & Regulatory

Germplasm (classical breeding)

Genetic Transformation

Events produced in the

Laboratory

First field trial / Event selection

Regulatory trial CTNBio¹ approval

Dossier submission

CTNBio¹ Approval

Note 1. CTNBio: Brazilian National Biosafety Committee Note 2. Team estimates

3 years²

CTNBio¹ Approval

3 years² 2 years² 1 year²

16

Our Business Building customer value

442k ha

Game changer: every 1% decreases land requirement by 4.4k hectares;

Less land: - Lower forest establishment

costs; - Lower input costs

Reduced mean radius to mill

Reduced pressure on natural resources

Planted area in 2013

Biotechnology drives sustainability

India 22%

Brazil 20%

China 14%

S. Africa 3%

Thailand 3%

ROW 39%

17

Our Business Brazilian Global forestry biotech champion

Sorce: RISI 2010 and Team estimates ROW: Rest of the World

Presence in territories representing 60% of the total eucalyptus global market (~20 million ha)

Three world class biotechnology centers (Brazil, China and Israel)

Presence in South East USA potential biomass energy market

Global network of R&D and commercial alliances

USA

Brazil 4.5 MM ha

India 3.9 MM ha

S. Africa 0.6 MM ha

China 3.0 MM ha

Thailand 0.5 MM ha

18

Our Business Sourcing the technologies of the future

18

The University of British Columbia

Oregon State University

The University of Arizona

Purdue University

UNESP

USP

The Hebrew University of

Jerusalem

Beijing Forestry University

China Academy of Forestry

Guangxi Academy

of Sciences

Note. Only Contractual relationships

UFV

Embrapa

The University of Mississippi

19

Our Business FuturaGene Portfolio

Biomass Accumulation

Nutrient Use Efficiency

Processability

Wood Quality

Polyploid

Gene Sourcing / Feasibility

Phase I – Proof of concept

Phase II – Early Stage

Phase III – Late Stage

Phase IV – Pre - launch

1 – 4 years 2 – 4 years 2 – 3 years 3 years 3 years

Yield Protection

20

Our Business FuturaGene in Brazil

FuturaGene Brazil

3.8 Ha campus at Itapetininga – laboratories, greenhouses and clonal banks;

Facility focused on Suzano and Brazilian partnerships;

Innovation Center for bioenergy crops;

Global regulatory and tree improvement activities run from Brazil.

21

Our Business FuturaGene in China

FuturaGene China

Fully operational R&D center in Shanghai;

Field trial farms in different geographies for specific tree crops;

Unique business license in China – genetic modification of forest species, export/import and sale of trees;

Focused on eucalyptus, poplar and desert species in China.

FuturaGene Israel

Focused on global partnerships, technology prototyping and training;

Global business development center;

International germplasm repository;

Intellectual property management.

22

Our Business FuturaGene in Israel

* Including 1 PhD in Barcelona.

23

Agenda Presentation to Goldman Sachs

▪ Introduction

▪ Why Biotech

▪ Our Business

▪ Summary

24

Summary FuturaGene: an Innovator of the green economy

First high value eucalyptus (15%-20% yield gain) in advanced regulatory phase in Brazil. First mover in Biotechnology has created a multi-year competitive time advantage for Suzano.

FuturaGene is the world leader in tree biotechnology - fully integrated capabilities from laboratory to field. Biotechnology is a “game changer”.

Pipeline addresses vital eucalyptus issues: additional yield, wood properties, pests, diseases, climate and soil adaptation. FuturaGene technologies applicable to multiple crops, providing additional monetization opportunities.

Value: each 1% yield gain represents a potential lowered land requirement of 4k ha. - lower forest establishment costs, lower input costs and reduced mean radius to mills.

FuturaGene scientific base is being utilized across additional technology platforms and couples conventional breeding techniques and biotechnology to develop traits of interest, enhancing Suzano’s forest base.

http://www.futuragene.com

Sustainability is enhancing Productivity whilst preserving today’s

Resources for tomorrow.